The prognosis for patients with osteosarcoma who have received prior manipulative therapy

Journal of Bone and Joint Surgery - Series B

Volumn 92 B, Issue 11, 2010, Pages 1580-1585

  Wu, P K ^a,b   Chen, W M ^a,b   Lee, O K ^a,b   Chen, C F ^a,b   Huang, C K ^a,b   Chen, T H ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHILD; FEMALE; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MANIPULATIVE MEDICINE; METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCULOSKELETAL MANIPULATIONS; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; PROGNOSIS;

EID: 78649407514     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.92B11.24706     Document Type: Article

References (37)

1. Sweetnam R. Osteosarcoma. Br J Hosp Med 1982;28:112, 116-21.
2. Mascarenhas L, Siegal S, Spector L, et al. Malignant bone tumors: cancer in 15- to 29-year-olds in the United States. In: Bleyer A, O'Leary M, Barr R, Ries LAG, eds. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age: including SEER incidence and survival, 1975-2000. Bethesda: National Cancer Institute, 2006:97-110.
3. Dahlin DC, Unni KK. Bone tumors: general aspects and data on 8,542 cases. Fourth ed. Springfield: Charles C Thomas, 1986.
4. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop 2007;459:40-7. (Pubitemid 46878192)
5. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995;75(Suppl):203-10.
6. Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome: the French pediatric experience. Cancer 2005;104:1100-9.
7. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001;12:1145-50.
8. Smeland S, Müller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488-94. (Pubitemid 36173693)
9. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-58.
10. Kaste SC, Liu T, Billups CA, et al. Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 2004;43:723-8. (Pubitemid 39557707)
11. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001;37:2030-9.
12. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
13. Huvos AG, Rosen G, Marcove RC, et al. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14-18.
14. Dune L. Integrating tuina acupressure and traditional Chinese medicine concepts into a holistic nursing practice. Explore (NY) 2006;2:543-6. (Pubitemid 44734504)
15. Wallach JB. Interpretation of diagnostic tests. Boston: Little, Brown, 1986.
16. Wuisman P, Enneking WF. Prognosis for patients who have osteosarcoma with skip metastasis. J Bone Joint Surg [Am] 1990;72-A:60-8.
17. Bacci G, Ferrari S, Sangiorgi L, et al. Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother 1994;6:204-10.
18. Saeter G, Alvegård TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991;9:1766-75.
19. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993;72:3227-38. (Pubitemid 23356765)
20. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German- Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-9.
21. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90.
22. Leavey PJ, Day MD, Booth T, Maale G. Skip metastasis in osteosarcoma. J Pediatr Hematol Oncol 2003;25:806-8.
23. Sajadi KR, Heck RK, Neel MD, et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop 2004;426:92-6.
24. Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer 1975;32:87-107.
25. Jaffe N. Chemotherapy in osteosarcoma. In: Muggia FM, ed. Experimental and clinical progress in cancer chemotherapy: advances and controversies. Boston: Martinus Nijhoff, 1986:223-33.
26. Harris MB, Geiser P, Gorrin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998;16:3641-8.
27. Goorin AM, Abelson HT, Frei E 3rd. Osteosarcoma: fifteen years later. N Engl J Med 1985;313:1637-43.
28. Marina NM, Pratt CB, Rao BN, Shema SJ, Meyer WH. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 1992;70:2722-7.
29. Bacci G, Picci P, Briccoli A, et al. Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori 1992;78:200-6.
30. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
31. Enneking WF, Kagan A. The implications of "skip" metastases in osteosarcoma. Clin Orthop 1975;111:33-41.
32. Malawer MM, Dunham WK. Skip metastases in osteosarcoma: recent experience. J Surg Oncol 1983;22:236-45.
33. Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-705. (Pubitemid 24379659)
34. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998;69:230-6.
35. Rosern G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163-77.
36. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002;20:2150-6. (Pubitemid 34408807)
37. Miniero R, Brach del Prever A, Vassallo E, et al. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Bone Marrow Transplant 1998;22(Suppl 5):37-40.